News
Fluidra Achieves Sales of €1,623 Million in the First Nine Months of 2023
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, achieved sales of €1,623 million in the first nine months of the year, down 16% compared to the
Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years
43rd Annual Fall Clinical Dermatology Conference
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced results from the long-term extension
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced the presentation of new data on lebrikizumab through 18 abstracts, including two oral
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that
Fluidra Achieves Sales of €1,186 Million in the First Half of the Year
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, achieved sales of €1,186 million in the first half of the year, down 18% compared to prior year
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.
Financial highlights (€ rounded million)
H1 2023
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri® (tildrakizumab) significantly improved wellbeing in patients with
Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing
Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of
Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase
Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital
Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase
Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre- emptive share capital increase (the “Capital Increase”) for
Fluidra Achieves Sales of €554 Million in the First Quarter and Maintains Its 2023 Guidance
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, achieved sales of €554 million euros in the first three months of the year, down 17% compared to a
Almirall’s First Quarter 2023 Results
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results.
Financial highlights (€ rounded million)
Q1 2023
Fluidra Closed 2022 with €2,389 Million Sales, up 9% on 2021
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, closed 2022 with sales of €2,389 million euros, up 9% compared to 2021, and EBITDA of 512 million
Almirall’s Full-Year 2022 Results
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.
Financial highlights (€ rounded million)
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San
Fluidra Reaches an Agreement to Acquire Meranus Group
Fluidra, global leader in pool and wellness equipment and connected solutions, today announces it has reached an agreement to acquire 100% of the Meranus Group, a leading distributor of pool
Almirall’s Nine-month 2022 Results
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.
Financial highlights (€ rounded million)
9M 2022
Fluidra Sales Grew by 15% in the First Nine Months of the Year
Fluidra, global leader in pool and wellness equipment and connected solutions, ended the first nine months of the year with sales of 1,967 million, up 15% on the same period of 2021. Sales grew
Fluidra provides update on its financial performance in Q3 and full-year outlook
Fluidra, global leader in pool and wellness equipment and connected solutions, today provided an update on its third quarter financial results and its full year outlook as trading conditions have
Clara Valera, New Investor Relations and Business Development Director at Fluidra
Fluidra, global leader in pool and wellness equipment and connected solutions, has appointed Clara Valera as new Investor Relations and Business Development Director, reporting directly to Xavier
Fluidra Sales Grew by 22% in the First Half of the Year
Fluidra, global leader in pool and wellness equipment and connected solutions, ended the first six months of the year with record sales of 1,445 million, up 21.8% on the first half of 2021. These
Fluidra Increases Sales by 31% Driven by Strong Demand, Price and M&A
Fluidra, global leader in pool and wellness equipment and connected solutions, closed the first quarter of the year with solid results driven by continued demand, price and the run rate of 2021 M&A
Fluidra Will Increase Its Dividend by More Than 110% With a Payout of 0.85 Euros Per Share
Fluidra, the global leader in the pool and wellness equipment sector, continues generating shareholder value in 2022. The Board of Directors has agreed to propose to the General Shareholders’
Fluidra Closes Record Year With €2.2 Billion Sales and €252 Million Net Profit
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, closed 2021 with its best results ever. The company ended the year with sales of 2,187 million
Fluidra Successfully Completes the Refinancing of Its Debt Structure and Links It to Its ESG Targets
Fluidra, the global leader in equipment and connected solutions in the pool and wellness sector, has successfully completed the refinancing of its debt structure, including a dual-currency senior